Hulskotte E G, Geretti A M, Osterhaus A D
Institute of Virology, Erasmus University Rotterdam, The Netherlands.
Vaccine. 1998 May-Jun;16(9-10):904-15. doi: 10.1016/s0264-410x(97)00292-2.
The development of a safe and effective vaccine for the prevention of AIDS has thus far proven to be extremely difficult, at least in part due to complexities associated with HIV-1 and its pathogenesis. The recent description of individuals transiently infected with HIV-1, as well as persons who survived HIV-1 infection for more than 15 years, indicates the ability of the immune response of certain individuals to control HIV-1 infection. Moreover, vaccination-challenge experiments in macaques infected with simian immunodeficiency virus have shown that protection against infection or development of disease may be achieved in the absence of sterilizing immunity, suggesting that the goals for AIDS vaccine development may have to be redefined. In addition, evaluation of new lentivirus vaccine strategies may largely benefit from the use of the newly developed chimeric simian-human immunodeficiency viruses, allowing the testing of HIV-1 antigen based vaccines in macaques.
迄今为止，开发一种安全有效的预防艾滋病疫苗被证明极其困难，至少部分原因是与HIV-1及其发病机制相关的复杂性。最近对短暂感染HIV-1的个体以及感染HIV-1超过15年仍存活的人的描述表明，某些个体的免疫反应有能力控制HIV-1感染。此外，对感染猿猴免疫缺陷病毒的猕猴进行的疫苗接种-攻毒实验表明，在没有完全清除病毒免疫力的情况下也可以实现预防感染或疾病发展，这表明可能需要重新定义艾滋病疫苗的开发目标。此外，评估新的慢病毒疫苗策略可能在很大程度上受益于新开发的嵌合猿猴-人类免疫缺陷病毒的使用，从而能够在猕猴中测试基于HIV-1抗原的疫苗。
